H.R.6577 - PRICED Act115th Congress (2017-2018)
|Sponsor:||Rep. Schakowsky, Janice D. [D-IL-9] (Introduced 07/26/2018)|
|Committees:||House - Energy and Commerce|
|Latest Action:||House - 07/27/2018 Referred to the Subcommittee on Health. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.6577 — 115th Congress (2017-2018)All Information (Except Text)
Introduced in House (07/26/2018)
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.
This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.